The abstract is read at the publisher; the summary is JClub's.
BT-115386, a MAT2A inhibitor, suppresses tumor growth and prolongs survival in mouse models of MTAP-deleted Epstein-Barr virus–associated nasopharyngeal carcinoma.
- Why it matters: EBV-associated nasopharyngeal carcinoma lacks targeted options, and MTAP loss creates a therapeutic vulnerability that needs a precision-matched strategy.
- What they did: Screening 200 NPC specimens found homozygous MTAP deletion in 37.5% (75/200); BT-115386 was then tested in MTAP-deleted NPC models, with PRMT5 activity, p53, MDM4 splicing, and c-Myc methylation assessed.
- The result: In MTAP-deleted NPC, BT-115386 reduces PRMT5 activity, enhances p53 via aberrant MDM4 splicing, and degrades c-Myc by abolishing arginine symmetric dimethylation, linking MAT2A/PRMT5 inhibition to multi-pathway tumor cell death.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.